SCOPE International AG   Report issue

For profit Phase 1 Phase 2
Founded: Mannheim Germany (2000)

Organization Overview

First Clinical Trial
2017
NCT03058224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

SCOPE International AG

Active Ingredients

Drugs in Phase 2 Trials (1)

pbf-680 (1 trial)

Drugs in Phase 1 Trials (1)

ob-002 (1 trial)

Drugs in Other Trials (2)

acetaminophen (tylenol) (1 trial)

polyclonal avian immunoglobulin igy containing specific igy against e. coli f18ab and s. typhimurium (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4